Prominently, the efficacy of checkpoint-inhibitor therapy in a small subgroup of PDAC patients with MMR-deficiency has initiated the era of personal medicine for pancreatic carcinoma patients and introduced the first FDA-approved treatment targeting a cellular stromal component. This evidence concerns the gene MRC1 and hyperinsulinemic hypoglycemia, familial, 4.